Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy
- PMID: 2868602
- DOI: 10.1530/acta.0.1110030
Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy
Abstract
Nine patients with severe Graves' ophthalmopathy were treated by intensive plasma exchange, followed by immunosuppression. Severity of ocular involvement and response to therapy were evaluated clinically by numerical scoring (ophthalmopathy index). Serum thyroid stimulating immunoglobulins (TSI) and urinary excretion of glycosaminoglycans (GAG) were measured immediately before and immediately after plasmapheresis. Plasma exchange was rapidly accompanied by marked clinical improvement in 8/9 patients. The most marked effects were on soft tissue involvement, proptosis, intraocular pressure, and visual acuity. The ophthalmopathy index decreased from 9.7 +/- 4.1 to 5.7 +/- 2.2 (P less than 0.001) after plasmapheresis. Serum TSI levels were initially elevated in 6 patients and remained positive in 3 patients after treatment. Urinary GAG excretion was initially 2- to 12-fold normal levels and was decreased by 60%. After plasmapheresis, patients received immunosuppressive drugs for 3-6 months. The follow-up period, after withdrawal of drugs, ranged from 5 to 38 months with a median of 17 months. The ocular condition remained stable in 6 patients. Three patients had a relapse 1 year after plasmapheresis: they were treated a second time by plasma exchange with subsequent improvement. In conclusion, intensive plasma exchange provided prompt and effective improvement in patients with severe progressive Graves' ophthalmopathy. This therapeutic procedure, followed by immunosuppression, gave long lasting results. Relapses were responsive to plasmapheresis therapy. The data suggest that plasma exchange may represent the best primary treatment for severe progressive Graves' ophthalmopathy.
Similar articles
-
Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy.Metab Pediatr Syst Ophthalmol (1985). 1988;11(3):133-40. Metab Pediatr Syst Ophthalmol (1985). 1988. PMID: 3205168
-
Plasma exchange therapy for severe Graves' ophthalmopathy.Horm Res. 1987;26(1-4):184-9. doi: 10.1159/000180699. Horm Res. 1987. PMID: 3596467
-
Urinary glycosaminoglycans in Graves' ophthalmopathy.Clin Endocrinol (Oxf). 1990 Jul;33(1):35-44. doi: 10.1111/j.1365-2265.1990.tb00463.x. Clin Endocrinol (Oxf). 1990. PMID: 2401097
-
Treating severe Graves' ophthalmopathy.Baillieres Clin Endocrinol Metab. 1997 Oct;11(3):521-36. doi: 10.1016/s0950-351x(97)80738-0. Baillieres Clin Endocrinol Metab. 1997. PMID: 9532337 Review.
-
Diagnosis of exophthalmos using orbital ultrasonography and treatment of malignant exophthalmos with steroid therapy, orbital radiation therapy, and plasmapheresis.Prog Clin Biol Res. 1983;116:189-205. Prog Clin Biol Res. 1983. PMID: 6134291 Review.
Cited by
-
Graves' ophthalmopathy.BMJ. 1990 May 26;300(6736):1352-3. doi: 10.1136/bmj.300.6736.1352. BMJ. 1990. PMID: 2196944 Free PMC article. Review. No abstract available.
-
Use of eye muscle antibody measurements to monitor response to plasmapheresis in patients with thyroid-associated ophthalmopathy.J Endocrinol Invest. 1993 Oct;16(9):669-74. doi: 10.1007/BF03348906. J Endocrinol Invest. 1993. PMID: 7904280
-
Immunosuppressant therapy of thyroid eye disease.Klin Wochenschr. 1988 Nov 1;66(21):1049-59. doi: 10.1007/BF01711917. Klin Wochenschr. 1988. PMID: 3070148 Review.
-
Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.BMJ. 1988 Dec 17;297(6663):1574-8. doi: 10.1136/bmj.297.6663.1574. BMJ. 1988. PMID: 2906260 Free PMC article.
-
An update on diagnostic methods in the investigation of diseases of the thyroid.Eur J Nucl Med. 1996 May;23(5):587-94. doi: 10.1007/BF00833398. Eur J Nucl Med. 1996. PMID: 8698068 Review.